T he world-wide spread of hep1titis C virus infection is enormous. It is estimated that approximately 3% of the world's population was infected with HCV, as well as 30 million people in China (mostly with HCV-1b). The majority (55%-85%) of patients with acute HCV infection will develop into chronic hepatitis and approximately 5%-25% of these patients will develop into cirrhosis. These patients are at high risk of liver failure, liver decompensation or hepatocellular carcinoma. Today, a combination of pegylated interferon alfa plus ribavirin (RBV) is considered as the standard of care (SOC) for patients with chronic hepatitis C, while the combination of interferon alfa and RBV is the second option. The purpose of this article is to evaluate receive treatment from January 2009 to January 2012 (68 men and 49 women; median age, 42 years old).
Criteria for exclusion were neutropenia (neutrophil count <1 500 per cubic millimeter); thrombocytopenia (platelet count < 90 000 per cubic millimeter); a creatinine concentration higher than 1.5 times of the upper limit of normal; coinfection with hepatitis A or B virus; decompensated liver disease; organ transplant; neoplastic disease; severe cardiac or chronic pulmonary disease; autoimmune disease (except well-controlled thyroid disease); a psychiatric disorder; women with pregnancy or lactation;an unwillingness for contraception.
Design
Eligible patients were assigned to receive either PEGASYS (135 μg or 180 μg/week, F. Hoffmann-La Roche, Shanghai, China) subcutaneously plus weightbased RBV (800 mg/d-1 200 mg/d, Shanghai Huashi Pharmaceutical Company) peros for 48 weeks, or 5 million units of interferon alfa-2a (Shenyang Sunshine Pharmaceutical Co., LTD) subcutaneously every other day, plus RBV as above for 48 weeks. Data on virology and biochemistry for all patients before treatment and at week 4, 12, 24, 36, 48 during treatment, and week 24 after treatment were collected. The differences between both groups were comapred and ALT and HCV RNA were quantified.
Characteristics
The two groups were matched for sex, age, weight, baseline ALT and AST levels and viral level (Table 1) .
Assessment and end points
Efficacy was assessed by measuring plasma HCV RNA and serum ALT. Virologic response was defined as undetectable levels of HCV RNA (with a lower limit of detection as 1 000 IU/ml). Biochemical response was defined as the presence of normal ALT and AST values (normalization of serum ALT and AST concentrations to a value ≤ upper limit of normal). The primary efficacy end points were a virologic and a biochemical response at week 72 (SVR). The differences between the two groups was comapred and ALT, AST and HCV RNA were detected.
Statistical analysis
Numerical data were described by mean ± standard deviation and analyzed by t test; while measurement data were analyzed by chi-square test. Two-sided P values were calculated for pairwise comparisons of the two treatment methods (accepting P < 0.05). All data were analyzed through statistic software SPSS (Statistical Program for Social Sciences) 16.0. Table 2) . Biochemical response between the two groups Sustained normalization of ALT concentrations at week 36, 48 and 72 were also more common in PEGASYS group than in IFNα group (Table 3) .
RESULTS

Efficacy
Effective factors influencing the virological response
We also explored the correlation between baseline HCV RNA level (＜1 million vs ≥1 million IU per milliliter) or ALT level and virological response. Base-line ALT level was calculated as the average of Table 1 . Characteristics of the patients at baseline serum ALT values before treatment, divided by the upper limit of normal (＜1, ≥1 and ＜3 vs ≥3 and ＜10) . Correlation between base-line RNA level and virological response It was suggested that HCV RNA level before medication had no effect on virological response in both groups (P > 0.05, respectively) ( Table 4) .
Correlation between base-line ALT quotient and virological response
In the study of the effects of ALT quotient before medication suggests that it had no effect on virological response in both groups (P＞0.05) ( Table 5) .
Safety
Adverse effects
A adverse effects occurred during the treatment such as infiuenza-like symptoms, myelosuppression, emotional disturbance and autoimmune disease, etc. The frequency and severity of adverse events were similar in both groups (P > 0.05) ( Table 6) .
DISCUSSION
Hepatitis C virus (HCV) infection is one of the major cause of chronic liver diseases, including cirrhosis, liver failure and hepatocellular carcinoma. Currently, no effective vaccine is available for HCV infection. Pegylated interferon in combination with ribavirin (RBV) is the standard of care (SOC) for patients with chronic hepatitis C. PEGASYS is a compound with sustained absorption, a slower rate of clearance and a longer half-life than unmodified interferon IFN α. It was Notes: † T test. Biochemical response was defined as the presence of normal ALT values (normalization of serum ALT concentrations to a value at or below the upper limit of normal). In this article, the reference value of normal serum ALT concentrations was ＜ 37 U/L. 4 Moreover, IL-28B gene polymorphisms were the strongest predictors of response to pegylated interferon and RBV in patients chronically infected with HCV genotypes 1 and 4. 5 Some studies found that the protective rs12979860 C allele frequency was 91.0%-97.5% in east Asia population, which may be the possible reason why domestic patients had a higher SVR than aboard. Therefore, therapy of CHC recently entered a new era with the deployment of direct-acting antivirals (DAAs), and IL-28B genotyping will be also useful for personalized CHC treatment in the forthcoming era of DAAs. 6 Our study also suggested that a regimen of PEGASYS plus RBV was associated with a higher rate of virologic response than IFNα group at weeks 4, 12, 36, 48 and 72. Sustained normalization of serum ALT concentrations at weeks 36, 48 and 72 were also more common in PEGASYS group than in IFNα group. Thus, PEG-IFNα-2a plus RBV had a significantly better efficacy than interferon alfa-2a plus RBV.
The therapeutic effect of interferon is influenced by multiple factors. [7] [8] [9] [10] Host factors are common, including age, weight, base-line ALT or AST level, alcohol-intake history, route of transmission, time of transmission, adiposis hepatica or HIV-infected concomitant or not and compliance. Virological factors are also frequent, such as genotypes, viral load and liver fibrosis, etc. Therapeutic factors contain dosage and dosage form of IFN, therapeutic alliance or not, for instance. Baseline factors are considered as predictable indexes of virological response. Some researchers applied multiple Logistic regression model to find that predictable factors concerning with SVR, such as γ-glutamyltransferase (GGT) concentration, viral genotypes and liver histologic characteristics, but not age, gender or weight index. While in our study, HCV RNA baseline levels had no effect on virological response in either PEGASYS group or IFNα group (also found in some domestic reports ).
11 Meanwhile, the baseline ALT level had no effect on virological response in both groups. It has been reported that the regimen of interferon plus RBV had little effects on HCV patients with normal ALT level, so it was not advised to use interferon on such patients but advised with followup in EASL (European Association for the Study of Liver) in 1999. 12 Studies on liver pathology found that even in patients with normal ALT quotient, 48%-87% of them already have chronic inflammation. 13,14 HCVinfected patients with serum ALT concentration below or above the upper limit of normal (but below tenfold of the upper limit) were enrolled into our study, and ALT level before medication was found to have no effect on virological response in the PEGASYS group and IFNα group. In PEGASYS group, the SVRs of patients with normal, slightly-increased and markedly-increased ALT level were 75.0%, 80.0% and 81.3%, respectively; which were 33.3%, 31.3% and 43.8% in IFNα group. In other words, in order to inhibit pathogenetic conditions from progressing, antiviral therapy especially pegylated interferon plus RBV should be administered for HCV infected patients with serum HCV RNA detectable but normal ALT level.
The profile of adverse drug reactions (ADRs) to interferon plus ribavirin has been well described. 15 The principal adverse effect of RBV is hemolytic anemia. Adverse effects associated with interferon includes fatigue, gastrointestinal disturbances, influenzalike symptoms, hematological abnormalities, neuropsychiatric effects (particularly depression), thyroid dysfunction, and dermatologic effects, such as alopecia and pruritus. The efficacy and safety profiles of PEGASYS plus RBV versus standard INF plus RBV were comapred, which suggested a qualitatively similar profile of ADRs. All symptoms were temporal after therapy termination.
In general, the combination of PEG-IFNα-2a and RBV is well tolerated, and laboratory abnormalities and adverse events associated with its administration were typical for those associated with unmodified IFNα. Therefore, a combination of PEG-IFNα-2a and RBV is a safe and effective treatment for Chinese patients with HCV infection.
